Zoe Finch Totten, Founder and Chief Executive Officer

For the past 20 years, Zoe has been developing and refining the vision for The Full Yield, Inc. She is committed to creating a jointly-built bridge between the healthcare and food industries to improve public health while reducing healthcare costs for employers and increasing profits for food retailers and manufacturers, and she believes this bridge has to be built with food. Zoe is an Associate with the Jefferson School of Population Health at Thomas Jefferson University, and a member of the Private and Public, Scientific, Academic, and Consumer Food Policy Group at Harvard Business School. Using cross-industry knowledge and an historic base in clinical and nutrition care, she has fostered partnerships to create market-disruptive employer-purchasing groups within the food industry and retailer-based healthy foods scoring programs. Zoe earned her MSN with honors from Yale University and her AB with honors from Vassar College.

Roger Dik, President and Chief Operating Officer

Roger brings 25 years of business and management consulting experience to The Full Yield, Inc. Roger was most recently a Partner at Accenture, where he advised consumer products companies worldwide on a variety of strategic issues and was also the managing partner of the B2B eBusiness and Supply Chain Transformation practices. Prior to consulting, he held brand management positions at The Quaker Oats Company and product development and manufacturing positions at General Foods Corporation.

 Roger earned his MBA in Finance and Marketing from the University of Chicago and his BS in Food Science from Cornell University.

Dee Bagshaw, Chief Research Officer

Dee brings 25 years of clinical and nutrition study management to The Full Yield, Inc. Dee most recently managed multiple large scale clinical operations for a leading cardiovascular nutrition research group, overseeing investigation, resource allocation, project planning, and operations detail. Previously, she was Director of Product Development for Zetachron, Inc, a pharmaceutical start-up purchased by Watson Pharmaceutical.